Is Netflix a Must-own Stock?
The early months of 2025 have been very hard on…
Sell
33
BIO Quote, Financials, Valuation and Earnings
Last price:
$242.46
Seasonality move
:
5.68%
Day range:
$235.81 - $247.52
52-week range:
$215.38 - $387.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.75x
P/B ratio:
1.06x
Volume:
222.6K
Avg. volume:
410.4K
1-year change:
-11.96%
Market cap:
$7B
Revenue:
$2.6B
EPS (TTM):
-$65.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories
|
$573.2M | $1.78 | -0.61% | -86.56% | $353.17 |
|
A
Agilent Technologies
|
$1.7B | $1.27 | 3.53% | 20.86% | $142.76 |
|
AVTR
Avantor
|
$1.6B | $0.23 | -4.32% | 159.99% | $22.35 |
|
BRKR
Bruker
|
$772.5M | $0.44 | 3.18% | 1050.16% | $60.13 |
|
RMD
ResMed
|
$1.3B | $2.36 | 7.98% | 23.74% | $264.15 |
|
RVTY
Revvity
|
$661.7M | $0.95 | 2.5% | 173.6% | $132.55 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories
|
$249.74 | $353.17 | $7B | -- | $0.00 | 0% | 2.75x |
|
A
Agilent Technologies
|
$106.28 | $142.76 | $30.3B | 24.43x | $0.25 | 0.91% | 4.70x |
|
AVTR
Avantor
|
$15.50 | $22.35 | $10.6B | 14.90x | $0.00 | 0% | 1.56x |
|
BRKR
Bruker
|
$38.97 | $60.13 | $5.9B | 51.28x | $0.05 | 0.51% | 1.73x |
|
RMD
ResMed
|
$236.10 | $264.15 | $34.6B | 26.50x | $0.53 | 0.88% | 6.93x |
|
RVTY
Revvity
|
$95.13 | $132.55 | $11.4B | 43.05x | $0.07 | 0.29% | 4.24x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories
|
15.46% | 1.613 | 13.06% | 4.53x |
|
A
Agilent Technologies
|
35.82% | 1.316 | 7.78% | 1.50x |
|
AVTR
Avantor
|
40.51% | 0.483 | 28.27% | 0.65x |
|
BRKR
Bruker
|
54.04% | 1.114 | 23.46% | 0.69x |
|
RMD
ResMed
|
10.82% | 0.237 | 2.05% | 1.99x |
|
RVTY
Revvity
|
29.13% | 0.972 | 23.4% | 2.75x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories
|
$341.9M | $58.3M | -20.67% | -23.87% | -134.35% | $81.2M |
|
A
Agilent Technologies
|
$899M | $376M | 13.98% | 20.82% | 23.5% | $334M |
|
AVTR
Avantor
|
$562.9M | $191.5M | 6.78% | 12.92% | 37.3% | $145.8M |
|
BRKR
Bruker
|
$493.3M | $157M | 3.22% | 6.78% | 7.32% | $153.3M |
|
RMD
ResMed
|
$766.4M | $426.3M | 22.47% | 25.76% | 33% | $554.9M |
|
RVTY
Revvity
|
$412.3M | $124.5M | 2.37% | 3.45% | 16.09% | $149.8M |
Bio-Rad Laboratories vs. Competitors
-
Which has Higher Returns BIO or A?
Agilent Technologies has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 18.92%. Bio-Rad Laboratories's return on equity of -23.87% beat Agilent Technologies's return on equity of 20.82%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B AAgilent Technologies53.48% $1.11 $9.4B -
What do Analysts Say About BIO or A?
Bio-Rad Laboratories has a consensus price target of $353.17, signalling upside risk potential of 41.41%. On the other hand Agilent Technologies has an analysts' consensus of $142.76 which suggests that it could grow by 34.33%. Given that Bio-Rad Laboratories has higher upside potential than Agilent Technologies, analysts believe Bio-Rad Laboratories is more attractive than Agilent Technologies.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories3 2 0 AAgilent Technologies8 10 0 -
Is BIO or A More Risky?
Bio-Rad Laboratories has a beta of 1.119, which suggesting that the stock is 11.924% more volatile than S&P 500. In comparison Agilent Technologies has a beta of 1.189, suggesting its more volatile than the S&P 500 by 18.904%.
-
Which is a Better Dividend Stock BIO or A?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agilent Technologies offers a yield of 0.91% to investors and pays a quarterly dividend of $0.25 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Agilent Technologies pays out 21.26% of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BIO or A?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than Agilent Technologies quarterly revenues of $1.7B. Bio-Rad Laboratories's net income of -$715.8M is lower than Agilent Technologies's net income of $318M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Agilent Technologies's PE ratio is 24.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.75x versus 4.70x for Agilent Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.75x -- $667.5M -$715.8M AAgilent Technologies4.70x 24.43x $1.7B $318M
-
Which has Higher Returns BIO or AVTR?
Avantor has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 29.67%. Bio-Rad Laboratories's return on equity of -23.87% beat Avantor's return on equity of 12.92%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B AVTRAvantor33.38% $0.73 $10B -
What do Analysts Say About BIO or AVTR?
Bio-Rad Laboratories has a consensus price target of $353.17, signalling upside risk potential of 41.41%. On the other hand Avantor has an analysts' consensus of $22.35 which suggests that it could grow by 44.21%. Given that Avantor has higher upside potential than Bio-Rad Laboratories, analysts believe Avantor is more attractive than Bio-Rad Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories3 2 0 AVTRAvantor8 8 0 -
Is BIO or AVTR More Risky?
Bio-Rad Laboratories has a beta of 1.119, which suggesting that the stock is 11.924% more volatile than S&P 500. In comparison Avantor has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.603%.
-
Which is a Better Dividend Stock BIO or AVTR?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avantor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Avantor pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIO or AVTR?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than Avantor quarterly revenues of $1.7B. Bio-Rad Laboratories's net income of -$715.8M is lower than Avantor's net income of $500.4M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Avantor's PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.75x versus 1.56x for Avantor. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.75x -- $667.5M -$715.8M AVTRAvantor1.56x 14.90x $1.7B $500.4M
-
Which has Higher Returns BIO or BRKR?
Bruker has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 1.4%. Bio-Rad Laboratories's return on equity of -23.87% beat Bruker's return on equity of 6.78%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B BRKRBruker50.36% $0.09 $3.9B -
What do Analysts Say About BIO or BRKR?
Bio-Rad Laboratories has a consensus price target of $353.17, signalling upside risk potential of 41.41%. On the other hand Bruker has an analysts' consensus of $60.13 which suggests that it could grow by 54.3%. Given that Bruker has higher upside potential than Bio-Rad Laboratories, analysts believe Bruker is more attractive than Bio-Rad Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories3 2 0 BRKRBruker6 7 0 -
Is BIO or BRKR More Risky?
Bio-Rad Laboratories has a beta of 1.119, which suggesting that the stock is 11.924% more volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.426%.
-
Which is a Better Dividend Stock BIO or BRKR?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.51% to investors and pays a quarterly dividend of $0.05 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BIO or BRKR?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than Bruker quarterly revenues of $979.6M. Bio-Rad Laboratories's net income of -$715.8M is lower than Bruker's net income of $13.7M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Bruker's PE ratio is 51.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.75x versus 1.73x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.75x -- $667.5M -$715.8M BRKRBruker1.73x 51.28x $979.6M $13.7M
-
Which has Higher Returns BIO or RMD?
ResMed has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 28.26%. Bio-Rad Laboratories's return on equity of -23.87% beat ResMed's return on equity of 25.76%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B RMDResMed59.33% $2.48 $6.2B -
What do Analysts Say About BIO or RMD?
Bio-Rad Laboratories has a consensus price target of $353.17, signalling upside risk potential of 41.41%. On the other hand ResMed has an analysts' consensus of $264.15 which suggests that it could grow by 11.88%. Given that Bio-Rad Laboratories has higher upside potential than ResMed, analysts believe Bio-Rad Laboratories is more attractive than ResMed.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories3 2 0 RMDResMed8 6 1 -
Is BIO or RMD More Risky?
Bio-Rad Laboratories has a beta of 1.119, which suggesting that the stock is 11.924% more volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.
-
Which is a Better Dividend Stock BIO or RMD?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.88% to investors and pays a quarterly dividend of $0.53 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BIO or RMD?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than ResMed quarterly revenues of $1.3B. Bio-Rad Laboratories's net income of -$715.8M is lower than ResMed's net income of $365M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while ResMed's PE ratio is 26.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.75x versus 6.93x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.75x -- $667.5M -$715.8M RMDResMed6.93x 26.50x $1.3B $365M
-
Which has Higher Returns BIO or RVTY?
Revvity has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 12.98%. Bio-Rad Laboratories's return on equity of -23.87% beat Revvity's return on equity of 3.45%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B RVTYRevvity56.53% $0.78 $10.8B -
What do Analysts Say About BIO or RVTY?
Bio-Rad Laboratories has a consensus price target of $353.17, signalling upside risk potential of 41.41%. On the other hand Revvity has an analysts' consensus of $132.55 which suggests that it could grow by 39.33%. Given that Bio-Rad Laboratories has higher upside potential than Revvity, analysts believe Bio-Rad Laboratories is more attractive than Revvity.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories3 2 0 RVTYRevvity9 7 0 -
Is BIO or RVTY More Risky?
Bio-Rad Laboratories has a beta of 1.119, which suggesting that the stock is 11.924% more volatile than S&P 500. In comparison Revvity has a beta of 1.068, suggesting its more volatile than the S&P 500 by 6.796%.
-
Which is a Better Dividend Stock BIO or RVTY?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revvity offers a yield of 0.29% to investors and pays a quarterly dividend of $0.07 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Revvity pays out 12.74% of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BIO or RVTY?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than Revvity quarterly revenues of $729.4M. Bio-Rad Laboratories's net income of -$715.8M is lower than Revvity's net income of $94.6M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Revvity's PE ratio is 43.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.75x versus 4.24x for Revvity. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.75x -- $667.5M -$715.8M RVTYRevvity4.24x 43.05x $729.4M $94.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Bill Ackman Buy Uber Stock?
In February, Pershing Square manager Bill Ackman revealed that his…
Should You Buy Alibaba Stock Despite the Risks?
Markets rebounded slightly after U.S. President Donald Trump announced a…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 36x
Alerts
Sell
48
FI alert for Apr 26
Fiserv [FI] is up 0.33% over the past day.
Buy
66
FARO alert for Apr 26
Faro Technologies [FARO] is up 0.93% over the past day.
Buy
55
PI alert for Apr 25
Impinj [PI] is up 2.15% over the past day.
